Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

27,850 32,200

Payables due to distribution agreement

partners 44,885 36,479

Accrued salaries and employee benefits 8,807 16,596

Accrued expenses and other current liabilities 31,196 27,518

Total current liabilities 312,738 312,793

Long-term debt, less current portion - -

Other long-term liabilities 32,108 30,975

Commitments and contingencies - -

Stockholders' equity

Preferred Stock, par value $0.0001 per share,

authorized 6,000,000 shares; none issued and

outstanding - -

Common Stock, par value $0.01 per share,

authorized 90,000,000 shares; issued

37,187,155 and 36,460,461 shares 372 364

Additional paid-in capital 282,033 274,963

Retained earnings 212,718 230,195

Accumulated other comprehensive loss (1,235) (1,362)

Treasury stock, at cost 2,666,226 and

2,604,977 shares (67,604) (66,405)

Total stockholders' equity 426,284 437,755

Total liabilities and stockholders' equity $771,130 $781,523

PAR PHARMACEUTICAL COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data)

(Unaudited)

Three Months Ended Six Months Ended

June 28, June 30, June 28, June 30,

2008 2007 2008 2007 <
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... 2014 METTLER TOLEDO is pleased ... ParticleView V19 with PVM technology , is ... vision and measurement tool continuously captures high-resolution images ... V19 then automatically prepares a report pairing the ... and concentration changes. This compelling blend of high ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... law firm of Finkelstein,Thompson LLP announces that a class ... Court for the Southern District of New York on,behalf ... GPC Biotech AG,("GPC Biotech" or the "Company") (Nasdaq: ... inclusive (the "Class Period"). Finkelstein Thompson LLP,is investigating similar ...
... BioSciences Inc.,(AMEX: YMI , TSX: YM, AIM: ... differentiated products for patients worldwide,today announced that Oncoscience ... of the humanized EGFR-targeting monoclonal antibody,nimotuzumab, has advised ... commence in Europe. - A ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... shareholders today that the Annual General Meeting ... been postponed due the geographical,nature of its ... of,proxy materials. The Company is currently working ...
Cached Biology Technology:Finkelstein Thompson LLP Announces GPC Biotech AG Investigation 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 3YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 4Sinovac Announces Postponement of Annual General Meeting 2
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... Stanford University research team has been awarded $6.27 million ... to be more energy efficient at home. The funding, ... U.S. Department of Energy,s Advanced Research Projects Agency-Energy (ARPA-E), ... come from Stanford and the California Energy Commission. ...
... skeleton made of segments, the vertebrae. During development of the embryo, ... head-end to the tail-end: the first segments to be added become ... ribs and the last ones the vertebra located in the tail ... it is crucial that, on the one hand, each segment, as ...
... October 27 2009 - The Government of Nepal announced today ... Landscape by 900 sq km, which will increase critical habitat ... at the inaugural session of the Kathmandu Global Tiger Workshop. ... government would establish a National Tiger Conservation Authority as well ...
Cached Biology News:Stanford researchers awarded $6.27 million to study energy efficiency and human behavior 2The skeleton: Size matters 2Nepal expands critical tiger habitat 2
... Reagent A - Fixation medium Reagent B ... intended for fixing cells in suspension with ... with Reagent B. This procedure gives antibodies ... morphological scatter characteristics of the cells intact. ...
... polyclonal to JNK1 (phospho T183 + Y185) ... domain containing phosphorylated T183/Y185. Reactivity / Specificity ... yet tested in other species. Background Information ... the ERK, JNK, and p38 kinases. The members ...
... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
... been designed to provide a thin film-like barrier when ... slide. This barrier creates the proper surface tension ... on the slide. PAP Pen contains a special ... It can be removed, if desired, by xylene after ...
Biology Products: